Re-Engineering Clostridial Neurotoxins for the Treatment of Chronic Pain
- 1 June 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in BioDrugs
- Vol. 24 (3), 173-182
- https://doi.org/10.2165/11534510-000000000-00000
Abstract
Clostridial neurotoxins from the botulinum neurotoxin (BoNT) family are protein complexes, derived from the bacterium Clostridium botulinum, which potently inhibit acetylcholine release and result in a reversible blockade of the neuromuscular junction. This feature led to the clinical development of BoNT-A for a number of neuromuscular disorders. BoNT-A toxins are commercially available as three different preparations: Dysport®/Azzalure®, Botox®/Vistabel®, and Xeomin®/Bocouture®. Although BoNT-A preparations have not yet been approved for the treatment of pain, a substantial body of preclinical and clinical evidence shows that BoNT-A is effective in treating a number of different types of pain. It is thought to exert an analgesic effect both via muscle-relaxant properties and also directly, via inhibition of nociceptive neuropeptides. This review explores the mechanistic basis of this analgesic effect, summarizing current knowledge of the structure-function relationship of BoNT and discussing effects on both motor and pain neurons. For a complete picture of the analgesic properties of BoNT-A, clinical evidence of efficacy in myofascial pain and neuropathic pain is considered in tandem with a mechanistic rationale for activity. Patients experiencing chronic pain are clear candidates for treatment with a modified clostridial endopeptidase that would provide enduring inhibition of neurotransmitter release. A strong preclinical evidence base underpins the concept that re-engineering of BoNT could be used to enhance the analgesic potential of this neurotoxin, and it is hoped that the first clinical studies examining re-engineered BoNT-A will confirm this potential.Keywords
This publication has 81 references indexed in Scilit:
- Engineering botulinum neurotoxin to extend therapeutic interventionProceedings of the National Academy of Sciences, 2009
- Glycosylated SV2A and SV2B Mediate the Entry of Botulinum Neurotoxin E into NeuronsMolecular Biology of the Cell, 2008
- Inside Information: The Unique Features of Visceral SensationMolecular Interventions, 2008
- Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammationBJU International, 2008
- A Double-Blind, Randomized, Placebo-Controlled Comparison of Botulinum Toxin Type A Injection Sites and Doses in the Prevention of Episodic MigrainePain Medicine, 2007
- Treatment of shoulder pain in spastic hemiplegia by reducing spasticity of the subscapular muscle: a randomised, double blind, placebo controlled study of botulinum toxin AJournal of Neurology, Neurosurgery & Psychiatry, 2007
- Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group StudyCephalalgia, 2006
- Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2005
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Effect of Botulinum Toxin A Injections in the Treatment of Chronic Tension‐type Headache: A Double‐Blind, Placebo‐Controlled TrialHeadache: The Journal of Head and Face Pain, 2001